Cardiovagal autonomic dysfunction in relation to HIV-associated lipodystrophy

被引:7
作者
Chow, DC
Wood, R
Grandinetti, A
Shikuma, C
Schatz, I
Low, P
机构
[1] Univ Hawaii Manoa, Dept Internal Med, Hawaii AIDS Clin Res Program, Honolulu, HI 96822 USA
[2] Univ Hawaii Manoa, Dept Pediat, Hawaii AIDS Clin Res Program, Honolulu, HI 96822 USA
[3] Louisiana State Univ, Dept Kinesiol, Baton Rouge, LA 70803 USA
[4] Univ Hawaii Manoa, Dept Publ Hlth & Epidemiol, Honolulu, HI 96822 USA
[5] Univ Hawaii Manoa, Dept Internal Med, Honolulu, HI 96822 USA
[6] Mayo Clin, Dept Neurol, Rochester, MN USA
来源
HIV CLINICAL TRIALS | 2006年 / 7卷 / 01期
关键词
autonomic function; HIV; lipodystrophy;
D O I
10.1310/B6PT-56HG-K3DN-84KK
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: Human immunodeficiency virus (HIV)-associated lipodystrophy (LD) may be mediated by changes in the autonomic nervous system. We examined the autonomic function among HIV-infected patients with LD compared to HIV-infected patients without LD (non-LD) and HIV-negative controls (controls). Method: This cross-sectional study examined cardiovagal autonomic function among the three groups. LD was defined in HIV-infected patients as increased visceral adipose accumulation and peripheral lipoatrophy. Cardiovagal autonomic testing was assessed by measuring heart rate variability during rest, paced breathing, and upright tilt and was analyzed in time and frequency domains. Results: Cardiovagal testing was performed on 58 participants: 26 controls, 20 non-LD, and 12 LD. After adjustment for visceral fat, time domain analysis showed decreased heart rate variability in patients with LD compared to the other groups (p < .05). The frequency domain analysis showed decreased high-frequency power and increased low- to high-frequency power ratio in the LD group compared to both groups during rest and to non-LD during tilt (p < .05). Conclusion: Patients with LD have altered cardiovagal modulation. Patients with LD had lower heart rate variability and higher sympathetic modulation compared to non-LD and controls. These alterations may be prognostic of increased cardiovascular disease morbidity and mortality.
引用
收藏
页码:16 / 23
页数:8
相关论文
共 50 条
[21]   The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection [J].
Guaraldi, G. ;
Stentarelli, C. ;
Zona, S. ;
Santoro, A. ;
Beghetto, B. ;
Carli, F. ;
Orlando, G. ;
Franceschetto, A. ;
Casolo, A. ;
Mussini, C. .
HIV MEDICINE, 2014, 15 (10) :587-594
[22]   Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities [J].
Guaraldi, Giovanni ;
Baraboutis, Ioannis G. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (03) :437-440
[23]   MRI of intra-abdominal fat and HIV-associated lipodystrophy: a case review [J].
Carlier, R. Y. ;
de Truchis, P. ;
Ronze, S. ;
Mompoint, D. ;
Vaue, C. ;
Melchoir, J. C. .
JOURNAL DE RADIOLOGIE, 2007, 88 (7-8) :947-956
[24]   Loss of subcutaneous adipose tissue in HIV-associated lipodystrophy is not due to accelerated apoptosis [J].
Mynarcik, D ;
Wei, LX ;
Komaroff, E ;
Ferris, R ;
McNurlan, M ;
Gelato, M .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (01) :53-56
[25]   HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways. [J].
Mallon P.W. ;
Carr A. ;
Cooper D.A. .
Current Diabetes Reports, 2002, 2 (2) :116-124
[27]   Soft tissue augmentation with PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy [J].
Serra, Marcio Soares ;
Goncalves, Leonardo Zacharias ;
Ramos-e-Silva, Marcia .
INTERNATIONAL JOURNAL OF STD & AIDS, 2015, 26 (04) :279-284
[28]   Investigation of SIRT1 gene variants in HIV-associated lipodystrophy and metabolic syndrome [J].
da Silva Tagliari, Carmela Farias ;
de Oliveira, Caren Nunes ;
Vogel, Greice Meyer ;
da Silva, Patricia Baptista ;
Linden, Rafael ;
Lazzaretti, Rosmeri Kuhmmer ;
Notti, Regina Kuhmmer ;
Sprinz, Eduardo ;
Mattevi, Vanessa Sune .
GENETICS AND MOLECULAR BIOLOGY, 2020, 43 (01)
[29]   Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome [J].
Feldt T. ;
Oette M. ;
Kroidl A. ;
Goebels K. ;
Fritzen R. ;
Kambergs J. ;
Kappert G. ;
Vogt C. ;
Wettstein M. ;
Häussinger D. .
Infection, 2006, 34 (2) :55-61
[30]   Recombinant Human Growth HormoneRationale for Use in the Treatment of HIV-Associated Lipodystrophy [J].
Stefano Benedini ;
Ileana Terruzzi ;
Adriano Lazzarin ;
Livio Luzi .
BioDrugs, 2008, 22 :101-112